High Rate of Drug Interaction Risks Found in Type 2 Diabetes Prescriptions in Indonesia

Ilustrasi By AI

FORMOSA NEWS - Lampung- A 2026 study by Harum Puspita Ningrum, Elma Viorentina Sembiring, and Ageng Hasna Fauziyah from the Pharmacy Department at the Health Polytechnic of Tanjung Karang reveals that most prescriptions for type 2 diabetes patients in Bandar Lampung carry potential drug interaction risks. Published in the Formosa Journal of Science and Technology, the research highlights that 76% of outpatient prescriptions analyzed in 2024 contained possible drug–drug interactions—findings that raise concerns about patient safety and treatment effectiveness.


Rising Diabetes Cases and Medication Complexity

Type 2 diabetes mellitus (T2DM) is one of the most common chronic diseases globally, including in Indonesia. In Lampung Province alone, more than 18,600 diabetes cases were recorded in Bandar Lampung in 2022, reflecting a growing public health burden.

As patients often require multiple medications to manage blood sugar and related conditions such as hypertension or cardiovascular disease, the risk of drug–drug interactions increases. These interactions can alter how medications work—either reducing their effectiveness or increasing the risk of harmful side effects.

This makes monitoring prescriptions a critical part of diabetes care, especially in outpatient settings where patients manage their treatment independently.

How the Study Was Conducted

The research team analyzed 100 medical records of type 2 diabetes outpatients treated at Advent Hospital in Bandar Lampung during 2024. The study used a descriptive quantitative design and selected records through accidental sampling.

Researchers reviewed prescriptions containing more than one medication and evaluated potential drug interactions using established drug databases, including Medscape, Drugs.com, and DrugBank.

They examined:

  • Patient demographics (age and gender)
  • Number and types of medications prescribed
  • Types of antidiabetic drugs used
  • Frequency, severity, and mechanisms of potential drug interactions

Key Findings: Most Prescriptions Carry Interaction Risks

The study found that drug interaction risks are widespread among diabetes patients:

  • 76% of prescriptions contained at least one potential drug–drug interaction
  • A total of 261 interaction cases were identified across 100 prescriptions
  • Moderate interactions dominated (63.2%), followed by minor (30.3%) and major (6.5%)

Common Patient Profile

  • 57% female, 43% male
  • 72% aged 46–65 years
  • Most prescriptions (87%) contained fewer than seven medications

Most Frequently Used Drugs

  • Metformin was the most prescribed drug (30.9%)
  • Sulfonylureas were the most common drug class (34.6%)

Most Common Interaction Types

  • Pharmacokinetic interactions (50.6%)—affecting drug absorption, metabolism, or excretion
  • Pharmacodynamic interactions (30.3%)—affecting how drugs act in the body
  • Unknown mechanisms (19.2%)

Frequently Identified Drug Combinations

  • Moderate risk: Ramipril + metformin (6.1%)
  • Minor risk: Metformin + vitamin B12 (15.2%)
  • Major risk: Lansoprazole + gliclazide (23.5%)

These combinations may increase risks such as hypoglycemia (dangerously low blood sugar), reduced drug effectiveness, or nutrient deficiencies.

Why These Findings Matter

Drug-drug interactions can significantly affect treatment outcomes in people with type 2 diabetes. Moderate interactions-while not immediately life-threatening-can still worsen side effects or require changes in therapy.

The study highlights that even prescriptions with fewer medications can still carry interaction risks, challenging the assumption that only “polypharmacy” (many drugs) leads to problems.

As the authors explain, the high rate of potential interactions “highlights the need for closer monitoring, improved evaluation of actual drug interactions, and enhanced patient education to reduce potential adverse outcomes.”

Real-World Implications for Healthcare

The findings have important implications for multiple stakeholders:

For Healthcare Providers

Doctors and pharmacists should:

  • Carefully review prescriptions for possible interactions
  • Monitor patients regularly, especially for blood glucose fluctuations
  • Adjust drug combinations when necessary

For Patients

Patients with diabetes should:

  • Inform healthcare providers about all medications they take
  • Follow prescriptions carefully
  • Report unusual symptoms such as dizziness, weakness, or hypoglycemia

For Health Systems and Policymakers

Hospitals and regulators may need to:

  • Strengthen clinical pharmacy services
  • Integrate drug interaction screening tools into prescribing systems
  • Promote guidelines for safer diabetes treatment

Expert Insight from the Researchers

The research team from the Health Polytechnic of Tanjung Karang emphasizes that drug interaction risks are not just theoretical but require practical attention in clinical care.

They note that many interactions—especially those involving metformin—are predictable and manageable with proper monitoring and awareness.

Author Profile

Harum Puspita Ningrum, S.Farm
Pharmacy researcher specializing in clinical pharmacology and drug safety
Health Polytechnic of Tanjung Karang, Indonesia

Elma Viorentina Sembiring, M.Farm
Lecturer and corresponding author in pharmaceutical sciences
Health Polytechnic of Tanjung Karang, Indonesia

Ageng Hasna Fauziyah, S.Farm
Researcher in pharmacy and medication management
Health Polytechnic of Tanjung Karang, Indonesia

Source

Title: Potential Drug–Drug Interactions in Prescriptions for Outpatients with Type 2 Diabetes Mellitus at A Private Hospital in Bandar Lampung
Journal: Formosa Journal of Science and Technology
Year: 2026

Posting Komentar

0 Komentar